Precision Biosciences

Precision Biosciences

Precision Biosciences was founded in 2006 by Jeff Smith, Matt Kane, and Derek Jantz — scientists who built the company around ARCUS, an engineered homing endonuclease they believed could outperform the zinc-finger and TALEN technologies dominant at the time. The firm went public in 2019 via a reverse merger, listing on Nasdaq under the ticker DTIL. While the founding wealth was scientific labor rather than a family fortune, the company has operated as an independent developer of genetic medicines for nearly two decades, headquartered in Durham, North Carolina. Precision's strategy originally spanned both therapeutic development and agricultural biotech. In the therapeutics segment, the company historically pursued an allogeneic CAR-T pipeline — most notably PBCAR0191 in partnership with Servier — alongside in vivo gene-editing programs for chronic hepatitis B and Duchenne muscular dystrophy. The agricultural division, which became Elo Life Systems in 2018 through a carve-out and external financing, applied ARCUS to crop improvement before operating independently. After clinical setbacks in the CAR-T programs, the company sharpened its focus on in vivo gene correction using lipid nanoparticle delivery, with PBGENE-HBV as the lead candidate entering clinical trials. The firm has also maintained an active business-development posture, signing a 2021 deal with Eli Lilly to apply ARCUS to Duchenne muscular dystrophy and other neuromuscular indications. As a clinical-stage biotech, Precision does not disclose assets under management in the traditional sense; its capital comes from equity markets and partnership revenues. The firm reported approximately $62 million in cash and cash equivalents at year-end 2024. In April 2024, the company announced a pipeline reprioritization that halted investment in the allogeneic CAR-T program to extend runway and concentrate resources on the in vivo pipeline, leading to a workforce reduction. CEO Michael Amoroso, appointed in 2021, has steered the company through this transition from a cell-therapy platform toward what management describes as a pure-play in vivo gene-editing company. What structurally differentiates Precision Biosciences is the ARCUS nuclease itself — a synthetic enzyme derived from an algal homing endonuclease that is smaller than CRISPR-Cas9 and makes staggered cuts, which the company argues enables more efficient gene insertion and repair. This fundamental molecular difference from the industry-standard CRISPR platform carries both promise and risk: it has attracted pharmaceutical collaborators including Lilly and Gilead, but has yet to produce a pivotal clinical readout that validates the platform's therapeutic advantage over competing gene-editing technologies.